Rog David J, Nurmikko Turo J, Friede Tim, Young Carolyn A
Walton Centre for Neurology and Neurosurgery, Liverpool, UK.
Clin J Pain. 2007 Jul-Aug;23(6):473-81. doi: 10.1097/AJP.0b013e31805d0c5d.
Central neuropathic pain occurs in around 28% of patients with multiple sclerosis (MS). The Neuropathic Pain Scale (NPS) has received preliminary validation in peripheral neuropathic pain conditions. The aim of this study was to validate its use in MS central pain syndromes.
We administered the NPS to 141 patients with MS, together with the Short Form McGill Pain Questionnaire (SFMPQ), the Hospital Anxiety and Depression Scale (HADS), and Short Form 36 Health Survey (SF-36).
Cronbach's alpha was 0.78 (95% CI 0.69; 0.83), implying a high degree of internal consistency. Three factors, "Familiar," "Superficial," and "Alien Perception," were extracted, accounting for 64% of the variance. The NPS 10-item total correlates with: the SFMPQ 15-item total score, rho=0.63 (95% CI 0.49; 0.74), its Visual Analog Scale, rho=0.49 (95% CI 0.33; 0.64), the transformed Pain domain of the SF-36 rho=-0.49 (95% CI -0.63; -0.32), but not with its remaining seven health domains, or with either the HADS anxiety or the depression scores. Limits of agreement for short-term test or re-test reliability of the 100 point NPS total (median 2 days, range 1 to 7) were -12 to 14 and when administered to 78 patients who rated their neuropathic pain the "Same" [median interval 33 days (range 19 to 126), the long-term test or re-test correlation coefficient was 0.71 (95% CI 0.6; 0.79)].
The NPS appears a useful tool in the assessment of neuropathic pain in MS patients and possibly in measuring outcomes of therapeutic interventions.
约28%的多发性硬化症（MS）患者会出现中枢神经性疼痛。神经性疼痛量表（NPS）已在外周神经性疼痛状况中得到初步验证。本研究的目的是验证其在MS中枢性疼痛综合征中的应用。
我们对141例MS患者进行了NPS评估，同时还使用了简化麦吉尔疼痛问卷（SFMPQ）、医院焦虑抑郁量表（HADS）和健康调查简表36（SF - 36）。
克朗巴哈系数为0.78（95%置信区间0.69；0.83），表明具有高度的内部一致性。提取了三个因素，即“熟悉”“浅表”和“异样感知”，它们解释了64%的方差。NPS的10项总分与以下各项相关：SFMPQ的15项总分，相关系数ρ = 0.63（95%置信区间0.49；0.74），其视觉模拟量表，ρ = 0.49（95%置信区间0.33；0.64），SF - 36转化后的疼痛领域，ρ = -0.49（95%置信区间 -0.63；-0.32），但与其余七个健康领域无关，也与HADS焦虑或抑郁评分无关。100分NPS总分的短期测试或重测信度（中位数2天，范围1至7天）的一致性界限为 -12至14，当对78例将其神经性疼痛评为“相同”的患者进行评估时[中位数间隔33天（范围19至126天）]，长期测试或重测相关系数为0.71（95%置信区间0.6；0.79）。
NPS似乎是评估MS患者神经性疼痛以及可能衡量治疗干预效果的有用工具。
